Thrombosis News and Research

Latest Thrombosis News and Research

Inflammation worsens danger due to atherosclerosis

Current research suggests that inflammation increases the risk of plaque rupture in atherosclerosis.

23 Jan 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).

1 Jan 2009

Drug eluting stents provide better outcomes that bare metal stents in angioplasty

Patients receiving drug eluting stents (DES) - stents coated with medication to prevent narrowing of the artery - as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJ.

18 Dec 2008

Abbott starts trial of 2.25 mm stent system

Abbott has announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System.

17 Dec 2008

Single letter in the human genome points to risk for high cholesterol

Write out every letter in the human genome, one A, C, T or G per millimeter, and the text would be 1,800 miles long, roughly the distance from New York to Colorado.

16 Dec 2008

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals has announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

10 Dec 2008

Protein could prevent blocked arteries

For the first time, researchers have found that a modified form of a naturally occurring protein, N-cadherin, could prevent blocked arteries. Blocked arteries are a major cause of heart attacks and strokes.

10 Dec 2008

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.

8 Dec 2008

New approaches to prevent blood clots

The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy presented December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Idiopathic pulmonary fibrosis linked to heart attacks

Patients with idiopathic pulmonary fibrosis (IPF) are three times as likely to experience severe coronary events - including heart attacks - than people without the disease, according to a recent study that analyzed the risk of cardiovascular disease in nearly 1,000 patients with IPF and more than 3,500 matched controls.

5 Dec 2008

Discovery of new enzyme in cancer growth

While studying the mechanics of blood clots, researchers at the University of Oklahoma Health Sciences Center discovered a new enzyme that not only affects the blood, but seems to play a primary role in how cancer tumors expand and spread throughout the body.

3 Dec 2008

Thrombosis patients face greater risks than previously believed

Deep venous thrombosis (DVT), the formation of blood clots in the lower limbs, is the third-most common vascular disease in North America after heart attack and stroke, and is a frequent complication in hospitalized patients.

3 Dec 2008

New cream for vaginal dryness approved

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream.

1 Dec 2008

Novel target for therapeutics against Staphylococcus aureus

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease.

28 Nov 2008

Blood transfusions increase clot risk in hospitalized cancer patients

Blood transfusions used to treat anemia in patients with cancer are associated with an increased risk of life-threatening blood clots, at a similar rate as other treatments for cancer-induced anemia, according to scientists at the University of Rochester Medical Center.

24 Nov 2008

Ultrasound helps provide rapid treatment of DVT

Scientists in the United States have discovered that ultrasound waves help dissolve blood clots in deep vein thrombosis (DVT) faster than clot-busting drugs.

24 Nov 2008

Neurological health risk in children with blunt head injuries: fashion hair beads

An intriguing article published in the December 2008 online issue of Journal of Neurosurgery: Pediatrics may come as quite a surprise to parents, especially those with little girls.

21 Nov 2008

Plastic surgeons warn of malnutrition in body contouring patients

Identifying malnutrition before surgery in massive weight loss patients seeking body contouring will significantly decrease surgical complications, accelerate wound healing, improve scar quality and boost patient energy levels, according to a study in the December issue of Plastic and Reconstructive Surgery ®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

16 Nov 2008

Nanomatrix stent coating designed to mimic natural endothelium

A nanomatrix for stent coating designed at the University of Alabama at Birmingham (UAB) mimics natural endothelium, the substance that lines blood vessels, and promises the potential to prevent post-operative tissue scaring along the blood vessel wall, greatly reducing the possibility of future thrombosis, or blockage at the stent site.

11 Nov 2008